A Retrospective Survey of Patients Undergoing Maintenance Hemodialysis vis-à-vis Cancer Prevalence
DOI:
https://doi.org/10.30683/1927-7229.2020.09.03Keywords:
Hemodialysis, cancer incidence, colorectal carcinoma, anticancer treatment.Abstract
The present study investigated the cancer prevalence and anticancer treatment patients undergoing hemodialysis at Nagoya Memorial Hospital. We retrospectively analyzed 663 patients undergoing hemodialysis between September 2014 and August 2019, including patient characteristics such as age, sex, and underlying diseases, cancer type, and cancer treatment. Seventy-eight patients (11.9%) of the dialysis population were diagnosed with cancer. Cancer type was then compared between registered cancer patients undergoing maintenance dialysis (N = 78) and non-dialysis controls (N = 3279) during the same period.
Colorectal carcinoma is the most common malignancy diagnosed in our hospital, accounting for approximately 15% of all types of cancers. The data of anticancer treatment for this disease were compared between dialysis patients (N = 15) and controls (N = 563), whose clinical stages were defined according to the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. Since the need to administer chemotherapeutic agents to dialysis patients with colorectal carcinoma will increase, oncologists should collaborate with nephrologists to cautiously manage anticancer treatment to avoid severe toxicities.
References
Cancer Statics in Japan-2019. https://ganjoho.jp/.../2019/ cancer_statistics_2019.pdf (15 October 2020, date last accessed)
Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, et al. FORFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. An Oncol 2015. https://doi.org/10.1093/annonc/mdv197 DOI: https://doi.org/10.1093/annonc/mdv197
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017; 66: 683-91. https://doi.org/10.1136/gutjnl-2015-310912 DOI: https://doi.org/10.1136/gutjnl-2015-310912
Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99. https://doi.org/10.1002/cncr.22329 DOI: https://doi.org/10.1016/S0140-6736(99)06154-1
Vajdic CM, McDonald SP, McCredie MRE, Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-31. https://doi.org/10.1001/jama.296.23.2823 DOI: https://doi.org/10.1001/jama.296.23.2823
Lin HF, Li YH, Wang CH, Chou CL, Kuo DJ, Fang TC. Increased risk of cancer in chronic dailysis patients: a population-based cohort study in Taiwan. Nephrol Dial Transplant 2012; 27: 1585-90. https://doi.org/10.1093/ndt/gfr464 DOI: https://doi.org/10.1093/ndt/gfr464
Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB, et al. Cancer incidence among US medicare ESRD patients receiving hemodialysis, 1996-2009. Am J Kidney Dis 2015; 65: 763-72. https://doi.org/10.1053/j.ajkd.2014.12.013 DOI: https://doi.org/10.1053/j.ajkd.2014.12.013
Kaizu K. The malignancy in chronic dialysis patients in Japan. J Jpn Soc Dial Ther 2015; 30: 499-504 (Japanese).
Cheung CY, Chan GCW, Chan SK, Ng F, Lam MF, Wong SSH, et al. Cancer incidence and mortality in chronic dialysis population: A multicenter cohort study. Am J Nephrol 2016; 43: 153-9. https://doi.org/10.1159/000445362 DOI: https://doi.org/10.1159/000445362
Kwon SK, Han JH, Kim HY, Kang G, Kang M, Kim YJ, et al. Cancer in patients on dialysis for end-stage renal disease : an international collaborative study. J Korean Med Sci 2019; 34. doi: org/10.3346/jkms.2019.34.e176. DOI: https://doi.org/10.3346/jkms.2019.34.e176
Mandayam S, Shahinian VB. Are chronic dialysis patients at increased risk for cancer ? J Nephrol 2008; 21: 166-74. www.jnephrol.com.
Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010; 23: 253-62. www.jnephrol.com.
Janus N, Launay-Vacher V, Byloos E, Machiels J-P, Duck L, Kerger J, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 2010; 103: 1815-21. https://doi.org/10.1038/sj.bjc.6605979 DOI: https://doi.org/10.1038/sj.bjc.6605979
Izzedine H, Perazella M. Onco-nephrology. Nephrol Dial Transplant 2015; 30: 1979-88. https://doi.org/10.1093/ndt/gfu387 DOI: https://doi.org/10.1093/ndt/gfu387
Janus N, Launay-Vacher V, Thyss A, Boulanger H, Moranne O, Islam MS, et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 2013; 24: 501-7. https://doi.org/10.1093/annonc/mds344 DOI: https://doi.org/10.1093/annonc/mds344
Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma Third English Edition 2019.
Komaki Y, Komaki F, Micic D, Ido A, Sakuraba. Risk of colorectal cancer in chronic kidney disease A systematic review and meta-analysis. J Clin Gastroenterol 2018; 52: 796-804. https://doi.org/10.1097/MCG.0000000000000880 DOI: https://doi.org/10.1097/MCG.0000000000000880
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 2019; 394: 1467-1480. https://doi.org/10.1016/S0140-6736(19)32319-0 DOI: https://doi.org/10.1016/S0140-6736(19)32319-0
Piawah S, Venook A. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer 2019; 125: 4139-4147. https://doi.org/10.1002/cncr.32163 DOI: https://doi.org/10.1002/cncr.32163
Rosner MH, Jhaveri KD, McMahon BA, Pedrazella MA. Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin 2020. https://doi.org/10.3322/caac.21636 DOI: https://doi.org/10.3322/caac.21636
